IN2012DN00650A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00650A
IN2012DN00650A IN650DEN2012A IN2012DN00650A IN 2012DN00650 A IN2012DN00650 A IN 2012DN00650A IN 650DEN2012 A IN650DEN2012 A IN 650DEN2012A IN 2012DN00650 A IN2012DN00650 A IN 2012DN00650A
Authority
IN
India
Prior art keywords
plant
chimeric influenza
vlps
influenza
vaccines
Prior art date
Application number
Inventor
Manon Couture
Michele Dargis
Pierre-Olivier Lavoie
LOUIS-PHILIPPE VéZINA
Aoust Marc-Andre D
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of IN2012DN00650A publication Critical patent/IN2012DN00650A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A method for synthesizing chimeric influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of chimeric influenza HA in a plant or a portion of a plant. The invention is also directed towards a VLP comprising chimeric influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding chimeric influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
IN650DEN2012 2009-06-24 2010-06-25 IN2012DN00650A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22016109P 2009-06-24 2009-06-24
PCT/CA2010/000983 WO2010148511A1 (en) 2009-06-24 2010-06-25 Chimeric influenza virus-like particles comprising hemagglutinin

Publications (1)

Publication Number Publication Date
IN2012DN00650A true IN2012DN00650A (en) 2015-06-12

Family

ID=43385835

Family Applications (1)

Application Number Title Priority Date Filing Date
IN650DEN2012 IN2012DN00650A (en) 2009-06-24 2010-06-25

Country Status (25)

Country Link
US (1) US10272148B2 (en)
EP (2) EP2445928B1 (en)
JP (2) JP5871796B2 (en)
KR (1) KR101377725B1 (en)
CN (1) CN102482328B (en)
AU (1) AU2010265766B2 (en)
BR (1) BRPI1015053A2 (en)
CA (1) CA2762042C (en)
DK (1) DK2445928T3 (en)
ES (1) ES2669303T3 (en)
HK (1) HK1245294A1 (en)
HR (1) HRP20180706T1 (en)
HU (1) HUE039100T2 (en)
IL (1) IL216937A (en)
IN (1) IN2012DN00650A (en)
MX (2) MX392585B (en)
MY (1) MY182643A (en)
NO (1) NO2445928T3 (en)
NZ (1) NZ597401A (en)
PL (1) PL2445928T3 (en)
PT (1) PT2445928T (en)
SG (1) SG176820A1 (en)
SI (1) SI2445928T1 (en)
WO (1) WO2010148511A1 (en)
ZA (1) ZA201200481B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CA2707235C (en) 2007-11-27 2013-11-19 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2730171C (en) * 2008-07-08 2016-10-11 Medicago Inc. Soluble recombinant influenza antigens
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
BRPI1015053A2 (en) 2009-06-24 2019-07-09 Medicago Inc chimeric influenza virus-like particles comprising hemagglutinin
CN102549008A (en) 2009-09-22 2012-07-04 麦迪卡格公司 Method for preparing protein of plant origin
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (en) 2010-03-30 2012-11-29 Sinai School Medicine Influenza virus vaccines and uses thereof.
TWI526539B (en) 2010-12-22 2016-03-21 苜蓿股份有限公司 Method for producing viroid-like particles (VLP) in plants and VLP produced by the method
US10202617B2 (en) * 2011-02-08 2019-02-12 Temasek Life Sciences Laboratory Limited Expression cassette for efficient surface display of antigenic proteins
TWI620816B (en) 2011-03-23 2018-04-11 苜蓿股份有限公司 Plant derived protein recovery method
LT3418300T (en) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CN116162175A (en) * 2011-09-20 2023-05-26 西奈山伊坎医学院 Influenza virus vaccine and application thereof
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
CN103930435A (en) 2011-09-30 2014-07-16 麦迪卡格公司 Increased yield of virus-like particles in plants
IN2015DN03070A (en) * 2012-11-27 2015-10-02 Univ Pittsburgh
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN112592389A (en) 2013-03-28 2021-04-02 莫迪卡戈公司 Production of influenza-like virus particles in plants
HK1222882A1 (en) * 2013-06-06 2017-07-14 Novartis Ag Influenza virus reassortment
AU2015205805B2 (en) * 2014-01-10 2020-11-12 Aramis Biotechnologies Inc. CPMV enhancer elements
ES2912291T3 (en) 2014-03-27 2022-05-25 Medicago Inc Modified CPMV Enhancer Items
CN105233302B (en) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 A kind of preparation method of influenza hemagglutinin glycopolypeptide multimer object nano particle
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20180088629A (en) 2015-07-02 2018-08-06 메디카고 인코포레이티드 Jasmonic Acid Pathway Activator
KR101755114B1 (en) * 2015-09-08 2017-07-06 건국대학교 산학협력단 A chimeric virus-like particle vaccine confers broadened antibody responses against different clades of highly pathogenic avian influenza H5 viruses
WO2017087492A1 (en) * 2015-11-16 2017-05-26 Kansas State University Research Foundation Influenza virus vaccine and vaccine platform
RU2022108149A (en) * 2016-02-03 2022-05-05 СиДжи ДИСКАВЕРИ, ИНК. INFLUENZA HEMAGLUTININ COMPOSITIONS WITH HETEROLOGUE EPITOPES AND/OR ALTERED CLEAVAGE SITES ON MATURATION
MX2018015755A (en) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Influenza virus hemagglutinin proteins and uses thereof.
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
JP6622825B2 (en) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Influenza A virus neutralizing antibody and method of use thereof
EP3765618A4 (en) 2018-03-14 2022-01-05 Medicago Inc. PLANT EXPRESSION ENHANCER
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
SG11202012314YA (en) 2018-06-27 2021-01-28 Medicago Inc Influenza virus hemagglutinin mutants
JP7512546B2 (en) 2019-03-14 2024-07-09 アラミス バイオテクノロジーズ インコーポレイテッド Endogenous plant-expressed enhancers
KR20210137485A (en) 2019-04-05 2021-11-17 아카데미아 시니카 Sialidase-resistant saccharides and methods of making and using the same
US20220267382A1 (en) * 2019-09-20 2022-08-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
JP2020048568A (en) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Influenza A virus neutralizing antibody and use thereof
TWI870591B (en) 2020-05-08 2025-01-21 中央研究院 Chimeric influenza vaccines
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
TW202334429A (en) 2021-10-01 2023-09-01 中央研究院 Antibody specific to spike protein of sars-cov-2 and uses thereof
EP4568709A2 (en) 2023-04-08 2025-06-18 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
ATE142883T1 (en) 1991-03-28 1996-10-15 Rooperol Na Nv COMPOSITIONS OF PHYTOSTEROLS WITH PHYTOSTEROLINS AS IMMUNE MODULATORS
UA48104C2 (en) 1991-10-04 2002-08-15 Новартіс Аг Dna fragment including sequence that codes an insecticide protein with optimization for corn, dna fragment providing directed preferable for the stem core expression of the structural gene of the plant related to it, dna fragment providing specific for the pollen expression of related to it structural gene in the plant, recombinant dna molecule, method for obtaining a coding sequence of the insecticide protein optimized for corn, method of corn plants protection at least against one pest insect
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6020169A (en) 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
WO2000009725A2 (en) 1998-08-11 2000-02-24 Biosource Technologies, Inc. Method for recovering proteins from the interstitial fluid of plant tissues
US6392121B1 (en) 1998-10-07 2002-05-21 Boyce Thompson Institute For Plant Research Gemini virus vectors for gene expression in plants
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (en) 1999-03-22 2003-05-16 Meristem Therapeutics CHEMICAL EXPRESSION PROMOTERS, EXPRESSION CASSETTES, PLASMIDS, VECTORS, PLANTS AND TRANSGENIC SEEDS CONTAINING THEM AND METHODS OF OBTAINING THEM
DK1173582T3 (en) * 1999-04-29 2006-10-23 Syngenta Ltd Herbicide resistant plants
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2435000C (en) 2001-01-18 2014-03-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
CA2816242C (en) * 2002-02-13 2019-01-08 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
BRPI0307679A2 (en) * 2002-02-13 2016-11-08 Wisconsin Alumni Res Found influenza viral vector, recombinant influenza virus, isolated nucleic acid molecule, and methods for expressing a heterologous nucleic acid segment in a cell and for preparing replication-incompetent influenza-like viruses.
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
EP1485492B1 (en) 2002-03-19 2011-12-21 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants
ES2224792B1 (en) 2002-06-28 2007-02-16 Era Plantech, S.L. PRODUCTION OF PEPTIDES AND PROTEINS BY ACCUMULATION OF PROTEIN BODIES DERIVED FROM ENDOPLASMIC RETICLES IN PLANTS.
AU2004235813B2 (en) 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US20040268442A1 (en) 2003-05-05 2004-12-30 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7226781B1 (en) 2003-07-24 2007-06-05 Belyaev Alexander S Chaperone expression genomes
ES2381200T3 (en) 2005-04-29 2012-05-24 University Of Cape Town Expression of viral proteins in plants
MX2008000890A (en) 2005-07-19 2008-03-18 Dow Global Technologies Inc Recombinant flu vaccines.
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
EP1945250A4 (en) 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE FOR INFLUENZA VIRUS
BRPI0617486A2 (en) 2005-10-18 2011-07-26 Novavax Inc vaccine comprising functional influenza virus (vlp) -like particles and use of an influenza vlp
KR20080106433A (en) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Influenza Antigens, Vaccine Compositions and Related Methods
US7993655B2 (en) 2006-04-21 2011-08-09 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
EP2023952B1 (en) 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2029755A1 (en) 2006-05-22 2009-03-04 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
US20070286873A1 (en) 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc Respiratory syncytial virus-virus like particle (vlps)
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
WO2008148104A1 (en) 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
ES2624776T3 (en) 2007-06-15 2017-07-17 Medicago Inc. Modified production of glycoproteins in plants
KR100964462B1 (en) 2007-07-10 2010-06-16 성균관대학교산학협력단 Avian Influenza Virus Vaccine Derived from Transgenic Plant and Its Manufacturing Method
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
BRPI0815662A2 (en) 2007-08-20 2016-09-27 Fraunhofer Usa Inc flu vaccines, antigens, compositions, and prophylactic and therapeutic methods
CA2707235C (en) * 2007-11-27 2013-11-19 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
KR101956910B1 (en) 2008-01-21 2019-03-12 메디카고 인코포레이티드 RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES(VLPs) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
CA2730171C (en) 2008-07-08 2016-10-11 Medicago Inc. Soluble recombinant influenza antigens
DK2318530T3 (en) 2008-07-18 2016-10-03 Medicago Inc Ny epitope to immunization against influenza
AU2009285667B2 (en) 2008-08-27 2015-05-28 Arizona Board Of Regents For And On Behalf Of Arizona State University A DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
US20100167376A1 (en) 2008-10-06 2010-07-01 Genvault Corporation Methods for providing cellular lysates from cell wall-containing samples
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
BRPI1015053A2 (en) 2009-06-24 2019-07-09 Medicago Inc chimeric influenza virus-like particles comprising hemagglutinin
CN102549008A (en) 2009-09-22 2012-07-04 麦迪卡格公司 Method for preparing protein of plant origin

Also Published As

Publication number Publication date
WO2010148511A8 (en) 2011-03-10
EP2445928A1 (en) 2012-05-02
IL216937A (en) 2017-01-31
HK1170250A1 (en) 2013-02-22
JP2012530499A (en) 2012-12-06
RU2012101946A (en) 2013-07-27
MX349924B (en) 2017-08-21
HUE039100T2 (en) 2018-12-28
EP2445928A4 (en) 2013-11-06
JP6141228B2 (en) 2017-06-07
AU2010265766B2 (en) 2015-03-19
HK1245294A1 (en) 2018-08-24
JP5871796B2 (en) 2016-03-01
HRP20180706T1 (en) 2018-06-01
KR20120133371A (en) 2012-12-10
JP2014158483A (en) 2014-09-04
CA2762042C (en) 2012-11-20
ZA201200481B (en) 2013-05-29
CA2762042A1 (en) 2010-12-29
RU2569195C2 (en) 2015-11-20
SG176820A1 (en) 2012-01-30
EP3228627A1 (en) 2017-10-11
NZ597401A (en) 2013-09-27
DK2445928T3 (en) 2018-05-28
US10272148B2 (en) 2019-04-30
US20120189658A1 (en) 2012-07-26
PT2445928T (en) 2018-06-07
CN102482328A (en) 2012-05-30
NO2445928T3 (en) 2018-08-25
EP2445928B1 (en) 2018-03-28
AU2010265766A1 (en) 2012-02-02
SI2445928T1 (en) 2018-05-31
MX2011013517A (en) 2012-05-23
PL2445928T3 (en) 2018-07-31
IL216937A0 (en) 2012-02-29
MY182643A (en) 2021-01-27
BRPI1015053A2 (en) 2019-07-09
WO2010148511A1 (en) 2010-12-29
MX392585B (en) 2025-03-19
CN102482328B (en) 2014-11-26
KR101377725B1 (en) 2014-03-27
ES2669303T3 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
IN2012DN00650A (en)
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MY161965A (en) New influenza virus immunizing epitope
WO2009076778A8 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2010003225A8 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
MX354750B (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs).
WO2011094358A9 (en) Influenza nucleic acid molecules and vaccines made therefrom
MX346245B (en) Fusion protein comprising diphtheria toxin non-toxic mutant crm197 or fragment thereof.
MX394097B (en) PRODUCTION OF VIRUS-LIKE PARTICLES IN PLANTS.
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
WO2010019262A3 (en) Polyvalent vaccine
MX354516B (en) Vectors encoding rod-derived cone viability factor.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
NZ622731A (en) Increasing virus-like particle yield in plants
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
DK201370530A (en) Salmonid alphavirus vaccine
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin
TH147611A (en) Cimeric influenza virus-like particles containing hemagglutinin